Clinical Variant Analysis: Part IV

· Andreas Scherer · Best Practices in Genetic Analysis, VSClinical

Rules for Combining Various Classification Criteria

Now that we have a solid understanding of how the various criteria are meant to be applied, it’s time to look at how the evidence collectively leads to the clinical categorization of a variant. Let’s go through the rule framework for combining the various criteria.

Pathogenic

In order for a variant to be classified as pathogenic, the following criteria have to be fulfilled.

  1. There is strong evidence for the PVS1 null variant criterion being fulfilled in conjunction with:
    1. 1 strong PS1-4 criterion or
    2. 2 moderate PM1-PM6 criterion being true or
    3. 1 moderate PM1-PM6 criterion is true and 1 supporting PP1-PP5 criterion or
    4. 2 or more supporting criteria PP1 – PP5 are true
  2. 2 or more strong PS1-PS4 criteria are true
  3. 1 strong PS1-PS4 criterion and:
    1. 3 or more  moderate PM1-PM6 criteria are true or
    2. 2 moderate PM1-PM6 and two or more supporting criteria PP1-PP5 or
    3. 1 moderate PM1-PM6 and four or more supporting criteria PP1-PP5

In all of this, it should be explicitly stated that without  clear literature evidence, a variant should never be classified as pathogenic.

Likely Pathogenic

The likely pathogenic classification has high clinical relevance. It makes stronger use of supporting criteria. A variant is likely pathogenic given the following:

  1. There is strong evidence for a PVS1 null variant and  1 moderate PM1 – PM6 criterion or
  2. 1 strong PS1-PS4 and 1-2 moderate PM1-PM6 criteria or
  3. 1 strong PS1-PS4 and 2 or more supporting criteria PP1-PP5 or
  4. 3 or more moderate criteria PM1-PM6 or
  5. 2 moderate PM1-PM6 and 2 or more supporting criteria PP1-PP5 or
  6. 1 moderate criterion PM1-PM6 and 4 or more supporting criteria PP1-PP5

Benign

The criteria for a benign classification are essentially very straightforward:

  1. 1 stand-alone BA1 criterion is fulfilled, which means the variant can be found in the standard population level catalogs at a frequency that rules out pathogenicity.
  2. There are 2 or more strong criteria BS1-BS4 fulfilled.

Likely Benign

The likely benign category makes use of supporting evidence. A variant is categorized as likely benign if the following is given:

  1. 1 strong criterion BS1-BS4 is true and 1 supporting evidence can be found BP1-BP7 or
  2. 2 or more supporting criteria BP1-BP7 are evident

To continue reading the classification criteria of pathogenic variants, please download a complimentary copy of “Clinical Variant Analysis” by clicking on the button below.

Leave a comment

Andreas Scherer

About Andreas Scherer

Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing. With its solutions, hundreds of the world’s hospitals and testing labs are able to harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. Golden Helix is also on the Inc 5000 list of the fastest-growing private companies in the US. He is also Managing Partner of Salto Partners, Inc, a management consulting firm headquartered in Nevada.  He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales, and operations. Clients are operating in the high-tech and life sciences space. Dr. Scherer holds a Ph.D. in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! 

View all posts by Andreas Scherer →